Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP-Cure-B: SLGN and NUC Discontinuation in Chronic Hepatitis B
NCT05045261Phase 2Unknown
- Sponsor
- ANRS
- Start
- Feb 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of selgantolimod in Chronic Hepatitis B (CHB), sponsored by ANRS. Status: unknown.
02
Drugs
selgantolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05045261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05045261.